Legend Biotech Management
Management criteria checks 1/4
Legend Biotech's CEO is Ying Huang, appointed in Sep 2020, has a tenure of 5.58 years. directly owns 0.067% of the company’s shares, worth $2.25M. The average tenure of the management team and the board of directors is 1.4 years and 3.7 years respectively.
Key information
Ying Huang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.07% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Legend Biotech (LEGN): The Cell Therapy Titan – Anticipating the 2026 Profitability Inflection.
Legend Biotech (LEGN) is a high-conviction play in the oncology sector, trading at $18.97 as of the March 6, 2026, market close. The company has moved beyond the typical "speculative biotech" phase and is now a commercial powerhouse, thanks to its lead CAR-T therapy, Carvykti (cilta-cel), developed in partnership with Johnson & Johnson.Why Investors Shouldn't Be Surprised By Legend Biotech Corporation's (NASDAQ:LEGN) 26% Share Price Plunge
Feb 06
Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds
Jan 23Investors Don't See Light At End Of Legend Biotech Corporation's (NASDAQ:LEGN) Tunnel And Push Stock Down 26%
Dec 11Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Aug 04There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) Massive 32% Price Jump
Jun 14
Expanding Facilities In Belgium And New Jersey Will Boost Reach
Expanded manufacturing and outpatient approval are set to increase supply and streamline distribution, potentially boosting net margins and revenue.Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)
Mar 11Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
Jan 07Some Legend Biotech Corporation (NASDAQ:LEGN) Shareholders Look For Exit As Shares Take 26% Pounding
Jan 02Legend Biotech: The Story Brightens
Dec 05Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12CEO
Ying Huang (52 yo)
Dr. Ying Huang, Ph D., is Chief Executive Officer of Legend Biotech Corporation since November 06, 2020 and serves as its Director since December 2021. Dr. Huang is Director of Third Arc Bio, Inc. He had b...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | no data | 0.067% $ 2.3m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Vice President of Finance | less than a year | no data | no data | |
| General Counsel | 2.4yrs | no data | no data | |
| Global Compliance Officer | less than a year | no data | no data | |
| President of Research & Development | no data | no data | no data | |
| Senior Vice President of Global Manufacturing & Supply | 2.4yrs | no data | no data | |
| President of CARVYKTI® | 1.4yrs | no data | no data | |
| Manager of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Manager of Investor Relations | no data | no data | no data |
Experienced Management: LEGN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | no data | 0.067% $ 2.3m | |
| Member of Strategic Advisory Board | 3yrs | no data | no data | |
| Independent Director | 5.9yrs | no data | 0.026% $ 865.1k | |
| Independent Director | 5.9yrs | no data | 0.025% $ 829.7k | |
| Independent Director | 3.7yrs | no data | 0.0098% $ 331.2k | |
| Independent Chairman | 3.7yrs | no data | no data | |
| Director | 10.9yrs | no data | 0.046% $ 1.5m | |
| Director | less than a year | no data | no data | |
| Member of Strategic Advisory Board | 3yrs | no data | no data | |
| Independent Director | 5.3yrs | no data | 0.024% $ 803.5k | |
| Independent Director | 3.7yrs | no data | 0.016% $ 542.3k | |
| Lead Independent Director | 1.7yrs | no data | 0.0072% $ 243.7k |
Experienced Board: LEGN's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 19:07 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Legend Biotech Corporation is covered by 30 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Etzer Darout | Barclays |
| Rick Bienkowski | Cantor Fitzgerald & Co. |